REMSleep Holdings Inc. Issues Shareholder Letter
Company Unveils Internal Corporate Goal of Capturing 10% of the CPAP Mask Market Within 24 Months CLEARWATER, Fla., August 6, 2024 – REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, published the following letter to shareholders. Dear REMSleep Shareholders and Interested Investors: Our company’s primary focus is two-fold. First, we are […]
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., August 5, 2024, — BioStem Technologies, Inc. (OTC: BSEM), a leading medtech company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, announced today that it will release its second quarter 2024 financial results after the […]
Vocodia Holdings Announces $2.8 million Preferred Stock Purchase Agreement as part of a $3.0 million Capital Raise
Boca Raton, FL, August 5, 2024 – Vocodia Holdings Corp (CBOE: VHAI) (“Vocodia” or the “Company”) a leader in AI software development focusing on practical AI applications, today announced the execution of a Securities Purchase Agreement (the “SPA”) and a Placement Agency Agreement marking a pivotal step in Vocodia’s strategic growth initiatives and capital structure […]
Oncocyte Announces August Investor Conferences Participation
IRVINE, Calif., August 5, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August: For additional details about the conferences or to schedule a one-on-one meeting with Oncocyte’s management team, please contact your Needham […]
Vocodia’s Demos Offer Human-Like AI Interactions
Chicago, August 2, 2024 — Vocodia Holdings Corp. (CBOE: VHAI), a pioneering AI software company specializing in practical AI solutions, today invites the public to try out one of four groundbreaking Conversational AI demos to see how Vocodia’s Digital Intelligent Sales Agents (DISA) actually work. Vocodia’s technology platform harnessed the power of conversational AI and […]
Direct Equity Source Announces Strategic Partnership with AAA Storage to Expand Self-Storage Portfolio
Austin, Texas, August 2, 2024 – Direct Equity Source, a leading real estate private equity firm, is pleased to announce a strategic partnership with AAA Storage, an industry-leading self-storage company. Direct Equity Source, via its recently formed fund, will be the largest single investor in AAA Storage’s current multi-property Growth Fund I, and significantly expand […]
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu […]
SPZI: Bloxcross and JP3E Announce the Global Trade Financing Platform Is Live
NEW YORK, August 1, 2024 – JP 3E Holdings, Inc. (OTC: SPZI), formerly Spooz, Inc., recently acquired a majority stake in Bloxcross, Inc. In the wake of this significant acquisition, they announce the launch of a new Global Trade Financing Platform, positioning Bloxcross as a key element of the JP3E portfolio. We expect that the […]
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Aug 1, 2024 – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company […]
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 2,066,000 shares of […]